Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.58 |
| ▸ | GSK3B | P49841 | 2/20 | 0.53 |
| ▸ | BACE1 | P56817 | 2/20 | 0.53 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | AGXT | P21549 | 2/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | CPA1 | P15085 | 1/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.45 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5514364 | 0.84 | MAOB (0.62) | MAOBGSK3BBACE1IDO1AGXT | |
| SCHEMBL3457379 | 0.84 | MAOB (0.58) | MAOBGSK3BBACE1IDO1AGXT | |
| SCHEMBL7024898 | 0.81 | MAOB (0.68) | MAOBGSK3BBACE1IDO1AGXT | |
| SCHEMBL17611474 | 0.81 | MAOB (0.59) | MAOBGSK3BBACE1IDO1AGXT | |
| SCHEMBL18937967 | 0.80 | MAOB (0.54) | MAOBGSK3BBACE1IDO1AGXT | |
| SCHEMBL4339666 | 0.80 | MAOB (0.61) | MAOBGSK3BBACE1IDO1AGXT | |
| SCHEMBL29118407 | 0.80 | MAOB (0.71) | MAOBIDO1 | |
| SCHEMBL13450401 | 0.80 | MAOB (0.60) | MAOBGSK3BBACE1IDO1AGXT | |
| SCHEMBL4836597 | 0.79 | MAOB (0.67) | MAOBAPP | |
| SCHEMBL4886506 | 0.77 | MAOB (0.58) | MAOBGSK3BBACE1IDO1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE39916-E1 | Compounds that modulate PPAR activity and methods for their preparation | WARNER LAMBERT COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-RE39916-E1 | Compounds that modulate PPAR activity and methods for their preparation | WARNER LAMBERT COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-RE39916-E1 | Compounds that modulate PPAR activity and methods for their preparation | WARNER LAMBERT COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-6964983-B2 | Compounds that modulate PPAR activity and methods for their preparation | WARNER-LAMBERT COMPANY, LLC (US) | 2005-11-15 | — | — | US | disclosed |
| US-6939875-B2 | Carbocyclic oxy sulfides such as [4-(Biphenyl-4-ylmethylsulfanyl)-5-methoxy-2-methyl-phenoxy]-acetic acid, used to control peroxisome proliferator activated receptors (PPAR), for prophylaxis of metabolic disorders | WARNER-LAMBERT COMPANY (US) | 2005-09-06 | — | — | US | disclosed |
| US-20050153996-A1 | COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS FOR THEIR PREPARATION | AUERBACH BRUCE J (US) | 2005-07-14 | — | — | US | disclosed |
| US-20050113440-A1 | Compounds that modulate PPAR activity and methods for their preparation | AUERBACH BRUCE J (US) | 2005-05-26 | — | — | US | disclosed |
| EP-1494989-A2 | COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS FOR THEIR PREPARATION | WARNER-LAMBERT COMPANY LLC (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20030225158-A1 | Compounds that modulate PPAR activity and methods for their preparation | WARNER-LAMBERT COMPANY | 2003-12-04 | — | — | US | disclosed |
| WO-2003084916-A2 | COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS FOR THEIR PREPARATION | WARNER-LAMBERT COMPANY LLC (US) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225158-A1 | Compounds that modulate PPAR activity and methods for their preparation | GPR119, PPARA, PPARG | MAOB 3512/4885GSK3B 1614/4885BACE1 2746/4885 |
| US-20050113440-A1 | Compounds that modulate PPAR activity and methods for their preparation | GPR119, PPARA, PPARG | MAOB 3512/4885GSK3B 1614/4885BACE1 2746/4885 |
| US-20050153996-A1 | COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS FOR THEIR PREPARATION | GPR119, PPARA, PPARG | MAOB 3512/4885GSK3B 1614/4885BACE1 2746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.